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Cdc25 phosphatase B, a potential target for cancer therapy, is inhibited by a series of quinones. 25 
The binding site and mode of quinone inhibitors to Cdc25B remains unclear, whereas this 26 
information is important for structure-based drug design. We investigated the potential binding 27 
site of NSC663284 [DA3003-1 or 6-chloro-7-(2-morpholin-4-yl-ethylamino)-quinoline-5, 8-28 
dione] through docking and molecular dynamics simulations. Of the two main binding sites 29 
suggested by docking, the molecular dynamics simulations only support one site for stable 30 
binding of the inhibitor. Binding sites in and near the Cdc25B catalytic site that have been 31 
suggested previously do not lead to stable binding in 50 ns molecular dynamics (MD) 32 
simulations. In contrast, a shallow pocket between the C-terminal helix and the catalytic site 33 
provides a favourable binding site that shows high stability. Two similar binding modes 34 
featuring protein-inhibitor interactions involving Tyr428, Arg482, Thr547 and Ser549 are 35 
identified by clustering analysis of all stable MD trajectories. The relatively flexible C-terminal 36 
region of Cdc25B contributes to inhibitor binding. The binding mode of NSC663284, identified 37 
through MD simulation, likely prevents the binding of protein substrates to Cdc25B. The 38 
present results provide useful information for the design of quinone inhibitors and their 39 
mechanism of inhibition. 40 




Cdc25B, as one of three human isoforms of the cell division cycle (CDC) phosphatase family, 43 
is an essential regulator in the cell cycle [1, 2]. It is reported to play an important role in S/G2 44 
(synthesis to gap 2) and G2/M (gap 2 to mitosis) phase transition by dephosphorylating 45 
CDK1/cyclin B at the centrosome level [3]. Cdc25B (but not Cdc25A or Cdc25C) is required 46 
for checkpoint recovery upon DNA-damage induced arrest of the G2 phase (and subsequent 47 
entry into mitosis) [4]. Overexpression of Cdc25 phosphatases in various human cancers is 48 
observed and reported, which makes Cdc25B a potential target for anticancer therapy [5-8]. 49 
The structure of the catalytic domain of Cdc25B is known [1] and various small molecules 50 
have been reported as potent inhibitors of Cdc25B [8-10]. Quinone-based structures are one of 51 
the most potent classes of Cdc25B inhibitors observed to date [9, 12]. NSC663284 was one of 52 
the quinolinediones first reported as a potential inhibitor (IC50, Cdc25B=0.21μM, see Figure 1) 53 
[13]. For many years, the compound has been used as a template to help design new inhibitors 54 
and to study the inhibition mechanism [14-16]. Initially, it was suggested that NSC663284 55 
could bind at one of the two anionic binding sites observed in the crystal structures of Cdc25B 56 
[12, 17]. In one of the crystal structures determined (PDB ID: 1QB0) [17], this site was 57 
identified by a sulfate ion interacting with the P-loop, a loop with the signature sequence 58 
HCX5R that contains the catalytic cysteine and forms part of the catalytic site in all protein 59 
tyrosine phosphatases (and thus  all Cdc25 phosphatases) [18]. The sulfate ion interacts with 60 
residues Arg479, Glu478, Ser477, Ser476, Phe475 and Glu474 [19, 20].  61 
No direct experimental identification of the binding mode of NSC663284 (or other quinone-62 
based inhibitors) to Cdc25B has been reported. A variety of molecular docking studies has 63 
studied the binding of NSC663284 and analogues to Cdc25B. Lavecchia et al. reported the 64 
docking of NSC663284 to the Cdc25B crystal structure using both the AutoDock and Gold 65 
programs [21]. AutoDock suggested a network of hydrogen bonds and electrostatic interactions 66 
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between the quinone carbonyl oxygens and residues Arg544, Arg482 and Tyr428. In this 67 
binding mode, the tail moiety is oriented toward the active site. Gold suggested a very different 68 
binding mode, with the quinolinedione ring placed into the active site. The authors suggested 69 
that the binding mode found by AutoDock could partially explain the mixed inhibition kinetics 70 
and the inhibition mechanism of Cys473 oxidation [22]. Arantes further studied the flexibility 71 
of Cdc25B and docked NSC663284 into the crystal structure and into structures obtained from 72 
conformational sampling [23]. Binding to the shallow pocket formed beside the P-loop, which 73 
is usually called ‘swimming pool’, was observed in docking to several sampled structures, in 74 
which the C-terminal helix had been partially unfolded. Several binding orientations were 75 
suggested where NSC663284 interacts directly with the P-loop. The author argued that these 76 
orientations provide possible explanations for the experimentally observed mixed inhibition 77 
kinetics and the irreversible oxidation of the catalytic residue Cys473. It is worth noting that 78 
the protein structure is rigid during docking in these previous docking studies [21,22]. Docking 79 
studies are also reported for other quinone-based inhibitors. Park H et al. reported three 80 
different binding modes of NSC 95397, dihydroxyl-NSC 95397 (D-NSC) and fluorinated NSC 81 
95397 (F-NSC) interacting with the P-loop of Cdc25B [24]. Docking of NSC 95397 followed 82 
by a single 2.1 ns MD simulation was performed by Ko et al. [25]. A shift of the NSC 95397 83 
binding pose was observed during the simulation, and comparison to simulation of the free 84 
Cdc25B indicated that the ligand may limit the flexibility of the C-terminal helix. Finally, 85 
Braud et al. reported a binding mode between a newly synthesized naphthoquinone derivative 86 
([(1,4-Dioxo-1,4-dihydronaphthalen-2-yl) methyl] malonic acid) and Cdc25B, in which the 87 
naphthoquinone core was placed outside of the P-loop [26].  88 
In summary, previous studies have revealed a range of possibilities for the binding site and 89 
binding mode between quinolinedione- and quinone-based inhibitors and Cdc25B. The binding 90 
sites identified can be classified as 1) within the catalytic site or 2) within the swimming pool 91 
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outside of the P-loop. The suggested binding orientations (or modes) are more varied. All 92 
suggested binding modes are obtained with molecular docking programs. It is clear that 93 
different programs (employing different algorithms and scoring functions) and/or settings can 94 
result in different orientations or even binding sites for the same ligand [27-29]. It is not known 95 
which combination of algorithm, scoring function and settings leads to the most reliable 96 
prediction of binding to Cdc25B, and it is thus not clear what the likely binding mode of 97 
quinolinedione inhibitors is. 98 
In this study, we first use molecular docking to find a variety of initial binding poses of 99 
NSC663284 to Cdc25B (using the crystal structure and alternative conformations sampled 100 
from MD simulation), and subsequently studied the stability of the main binding modes 101 
suggested by docking using extensive MD simulation. The simulations identified one binding 102 
site where NSC663284 can bind with relative high stability. Similar interactions between 103 
CdC25B and the ligand are observed during simulations starting from different poses in this 104 
binding site. Notably, our results indicate that binding of NSC663284 directly to the catalytic 105 
site (P-loop) as reported previously is likely to be unstable [23]. Our simulations and analyses 106 
provide new insights into the likely binding site, mode and interactions of quinolinedione 107 
inhibitors for Cdc25B, which will assist drug design and pharmacophore studies of 108 
quinolinedione-based Cdc25 inhibitors. 109 
 110 
Methods 111 
System setup for docking experiments 112 
The structure of NSC663284 (Figure 1) was built using SYBYL software package [30]. 113 
Geometric optimizations were carried out with the SYBYL/MAXIMIN2 minimizer with the 114 
TRIPOS force field (convergence criterion: RMS gradient of forces 0.05 kcal·mol-1 or less).  115 
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Crystal structures of cdc25B phosphatase were investigated and compared (table S1). PDB ID 116 
1QB0 [17] was selected for docking and simulation. Compared with the other structures (that 117 
are very similar), 1QB0 covers most of the sequence (without any mutations), including 118 
coordinates for residues Asp374 to Ala550, as well as the amide nitrogen of Ala551 of the 119 
Cdc25B primary sequence. The resolution is reasonably high (1.9 Å). Protonation states were 120 
investigated using the H++ Server [31]. Cys473 was predicted to be in the thiolate form. Four 121 
histidine residues (His375, His395, His519 and His533) were protonated at Nε and two 122 
histidine residues (His436 and His472) were protonated at Nδ, according to the Optimal 123 
Hydrogen Bonding Newtork (as determined using the WHAT-IF server, 124 
http://swift.cmbi.ru.nl/servers/html/index.html). All other residues were configured in their 125 
standard protonation states at pH 7.  126 
Docking of NSC663284 and clustering 127 
Two docking programs were used: AutoDock Vina and AutoDock 4.2 [32-34]. 128 
AutoDockTools 1.5.6 was used to prepare the input files. The grid box was centred on the SG 129 
atom of Cys473 with a size that allowed the ligand to be docked up to 11 Å (small grid box) 130 
and 18 Å (large grid box) away from the catalytic residue Cys473. The ligand and protein 131 
prepared as described above were imported, and non-polar hydrogens were merged. Partial 132 
charges calculated with the Gasteiger-Marsilli method using SYBYL were used for the ligand. 133 
Kollman partial charges were assigned to the protein. Docking with AutoDock Vina was 134 
performed with the default parameters. For AutoDock 4.2, exhaustive docking was performed 135 
in the small grid box (60 points of 0.375 Å spacing in each dimension) by using a population 136 
of 1500 and performing 1000 Lamarckian Genetic Algorithm (GA-LS) runs. The maximum 137 
number of generations and energy evaluations were set as 2.7×104 and 2.5×106 respectively. 138 
The 1000 poses generated were clustered according to root mean-squared deviation (RMSD) 139 
of the ligand heavy atoms with a 4.0 Å cut off. For the 7 clusters with the highest population, 140 
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the coordinates of the conformations with the lowest predicted binding energy were used for 141 
further MD simulation. Since the binding pose in the 11st highest populated cluster was similar 142 
to that reported previously by Lavecchia et al. (using Gold as the docking program) [20], 143 
coordinates with the lowest binding energy were also used for further MD simulation (complex 144 
2f, see below). The best docking mode obtained from Autodock Vina with small grid box was 145 
used as the starting structure (for MD simulation) named complex 1a. Another binding mode 146 
obtained with the larger grid box was used and named complex 3a. Additional starting 147 
structures complex 1b, 1c and 2a-2f were obtained from the Autodock 4.2 docking results. 148 
To obtain additional binding modes between the ligand and protein structures from MD 149 
simulation, NSC663284 was docked into 8 representative structures obtained from clustering 150 
of the apo protein MD simulations using Autodock Vina. (The apo protein MD simulation and 151 
clustering are described in the following section.) Among all eight docking modes obtained, 152 
one conformation was significantly different from those obtained by docking into the crystal 153 
structure, which was studied further as complex 2g. 154 
 155 
Molecular dynamics simulations 156 
The crystal structure of Cdc25B used as the starting structure for MD simulation was prepared 157 
as described above. For the NSC663284 ligand, partial atomic charges consistent with the 158 
Amber force-field used (RESP fitting of the HF/6-31G optimized structure) were calculated 159 
using the R.E.D server [35, 36].  GAFF force field parameters together with these charges were 160 
used for the ligand. To study the solution structure of the Cdc25B catalytic domain without 161 
inhibitor, the protein was also simulated without ligand (apo protein) [37]. The apo protein and 162 
the complexes obtained from docking were prepared for simulation using the Amber ff12SB 163 
force field for the protein [38-39] and solvation in a rectangular box of TIP3P water [40], with 164 
a minimum distance between the protein and the box edge of 11 Å. The crystal structure has 165 
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fewer residues defined at the C-terminus than the construct used for crystallisation (as well as 166 
the natural Cdc25B). Since the negative charge on the introduced Ala551 carboxylate terminus 167 
may influence the protein-ligand dynamics in site I, three different structures were built 168 
employing different C-terminal ends. The first C-terminal end was at Ala551 with a C-terminal 169 
carboxylate group (the apo system is hereafter referred to as ‘1qb0_OXT’). The second was 170 
modified with an N-methyl cap on the C-terminal Ala551 residue (the apo system is hereafter 171 
referred to as ‘1qb0_NME’). The third was built with two additional residues (Gly552 and 172 
Glu553 according to protein sequence), with Glu553 capped by an N-methyl group (the apo 173 
system is hereafter referred to as ‘1qb0_TWO’). Models with more residues were not 174 
considered because of the high uncertainty of the additional coordinates and the fact that the 175 
docking poses obtained would not be in contact with such additional residues. Gly552 and 176 
Glu553 were energy minimized for 1000 steps before performing the standard equilibration 177 
protocol as outlined below. All three receptor structures with different forms of C-terminal 178 
ends were used for further simulation. The total charge of the 1qbo_NME and 1qb0_TWO 179 
models was −1 and that of 1qb0_OXT was −2. To neutralize the systems, one or two Na+ 180 
counter ions were added. The complex structures are referred to by adding the relevant suffix 181 
“OXT/NME/TWO” (e.g. 1a_OXT).  182 
Optimization and equilibration protocols were applied to all systems before running production 183 
MD simulation. Initial optimization of the solvent consisted of 1000 cycles of energy 184 
minimization followed by 50ps of MD simulation at 298K (applying a positional restraint of 185 
100 kcal mol−1 Å−2 on all solute atoms). The whole system was then optimized by 1000 cycles 186 
of energy minimization with a mild positional restraint on the protein Cα atoms (2.0 mol−1 Å−2). 187 
All equilibration and production simulations were performed with the pmemd.cuda module 188 
and the default Mixed Single/Double/Fixed Point precision model. To prepare for production 189 
simulations, first, the temperature was increased from 50 to 298 K over a period of 50 ps 190 
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(maintaining the mild restraint on Cα atoms). Second, 200 ps simulation in the NPT ensemble 191 
at 298 K and a pressure of 1 bar was performed, again maintaining the mild restraint on Cα 192 
atoms. Thereafter, the whole system was briefly further equilibrated by 100 ps of NPT MD 193 
simulation (298 K, 1 bar). After this equilibration procedure, 50 ns MD simulation in the NPT 194 
ensemble at 298 K and 1 bar was carried out. Throughout, periodic boundary conditions were 195 
applied and the SHAKE algorithm was applied to fix all bond lengths involving hydrogen 196 
atoms. Temperature was maintained using langevin dynamics (collision frequency of 2 ps−1) 197 
and pressure with the Berendsen barostat (pressure relaxation time of 1 ps). A time step of 2 fs 198 
was used, with a direct-space cut off radius of 8.0 Å for non-bonded interactions and particle-199 
mesh Ewald for long-range electrostatic interactions. The trajectory was sampled every 2 ps 200 
(1000 steps intervals) for analysis. In total, three different apo protein systems and ten protein 201 
bound systems were simulated. Two independent runs were carried out for each system. 202 
Analysis of molecular dynamics simulations 203 
The AmberTools programs ptraj and cpptraj were used for trajectory analysis. Simulations 204 
were visualised using VMD (http://www.ks.uiuc.edu/Research/vmd/) [41]. The snapshots of two 205 
MD simulated trajectories of apo protein system 1qb0_OXT were clustered into 8 different 206 
clusters using Average Linkage and the root-mean-square of the Cα atoms of the stable part of 207 
the structure as the distance metric (residues 388-412, 418-455, 465-494 and 504-551). 208 
Representative structures (cluster centroids) from the clusters with occurrence larger than 1% 209 
were considered in docking experiments (see above). The RMSF values of the apo protein 210 
systems were calculated after alignment on the average structure of the 50 ns trajectory. After 211 
aligning the Cα atoms of the protein, the RMSD of the ligand heavy atoms with respect to the 212 
staring binding position was measured, in reference to the protein. Clustering of all stable 213 
protein-ligand trajectories was carried out on the distance between weight centres of atoms N, 214 
O and O1 on the ligand and the Cα atoms of Cys426, Leu445 and Arg479 (Supplementary 215 
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figure S1). DSSP secondary structure assignment was performed using WORDOM [42, 43]. 216 
The definition of the measured distances between pairs of residues within the identified binding 217 
site is listed in Table S2.  218 
 219 
Results and discussion 220 
Flexibility of Cdc25B phosphatase and stability of the C-terminal helix  221 
To investigate the solution structure and flexibility of the Cdc25B catalytic domain in absence 222 
of the ligand, several molecular dynamic simulations of 50 ns were carried out in explicit water, 223 
based on the crystal structure of the catalytic domain of human Cdc25B obtained at 1.9 Å 224 
resolution (PDB ID: 1QB0). Three different forms of the C-terminal end of the domain were 225 
considered: 1qb0_OXT – residues 374-551 with a C-terminal carboxylate; 1qb0_NME – 226 
residues 374-551 with an N-methylamide C-terminal cap; and 1qb0_TWO – residues 374-553 227 
(Gly552 and Glu553 modelled on and an N-methylamide cap on Glu553 C-terminus). Overall, 228 
the structure of the Cdc25B domain remains stable during all simulations, except for the largely 229 
unstructured and flexible 6 C-terminal residues (8 for the 1qb0_TWO construct). The average 230 
Cα RMSD values without the C-terminal residues for the final 25 ns of simulation range from 231 
1.23 Å to 1.43 Å (apart for 1qb0_NME run 2, where the C-terminal helix shifts its position). 232 
The flexibility (root mean square fluctuation of Cα atoms, RMSF) of the three constructs was 233 
similar, with the pattern in line with the B-factors of the crystal structure (Figure 2). Due to the 234 
absence of residues beyond the length of the simulated construct, high RMSF values were 235 
measured at the N- and C-terminal residues in all simulations (typically > 2 Å) as expected. 236 
RMSF values higher than for the remainder of the protein were also observed for residues 447-237 
464 (1-2 Å). Higher flexibility of this region is expected, as it is the binding site of phosphate 238 
esters [44]. In some simulations, a change in position was also observed for the C-terminal 239 
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helix A (residues 534-546), which lies largely outside of the globular core of the Cdc25B 240 
catalytic domain (see Figure S2). This region is possibly disordered in Cdc25A [45] and a 241 
previous single 60 ns MD simulation of Cdc25B reported “a local unfolding and detachment 242 
from the protein main-body” for helix A in Cdc25B [22]. In our simulations, only a small 243 
positional shift of the helix A was observed occasionally, but no unfolding. The overall 244 
conformation of the Cdc25B catalytic domain in the simulations is thus very similar as the 245 
crystal structure, and reasonably stable. This is consistent with recent structural studies of 246 
Cdc25B that came to the same conclusions based on NMR measurements and molecular 247 
dynamics simulation [46, 47].  248 
To further investigate the stability of the C-terminal helix A (defined in 1QB0.pdb as residues 249 
534-546), the secondary structure of the last 19 residues (H533-A551) was determined for apo 250 
protein simulations with C-terminus of OXT and NME, as well as the last 21 residues (H533-251 
E553) for C-terminus of TWO (Figure S3). For all three systems, region K537-K546 remains 252 
α-helical for the majority of the simulation time, and L540-F543 essentially the whole time. 253 
Residues H533-F536 show a 310-helix for about 10-30% of the 50 ns simulations. The last five 254 
residues T547-A551 do not show any regular secondary structure (apart from some helicity in 255 
1qb0_NME run 2). These observations are in agreement with the NMR residual dipolar 256 
coupling measurements and molecular dynamics simulations of a Cdc25B protein construct 257 
that contains the C-terminal tail up to Q566 [47]. Our analysis thus indicates that the C-terminal 258 
helix is realistically stable in our truncated models, independent of the C-terminal cap at or 259 
beyond Ala551.  260 
Initial binding modes identified by docking 261 
NSC663284 was docked into the Cdc25B crystal structure (PDB ID: 1QB0) as well as 262 
representative structures from MD simulations. We define three major binding sites: site Ι , site 263 
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ΙΙ and site III (Figure 3). Site I is a pocket between the C-terminal helix A and the P-loop, and 264 
includes the site commonly referred to as the ‘swimming pool’. It does not face the catalytic 265 
site directly. Site II is a shallow pocket above the P-loop. In contrast to site I, it allows direct 266 
and close contact with the catalytic residue Cys473, and is therefore commonly referred to as 267 
the ‘active site’. Both two sites have been mentioned by previous docking studies as potential 268 
binding sites for quinolinedione inhibitors [22-26]. Site III is a pocket flanked by helix B and 269 
several loops. It has been reported as the main region taking responsible protein-protein 270 
interaction. The inhibitor 2-fluoro-4-hydroxybenzonitrile (referred as 3M8 in the following, 271 
consistent with its residue name in PDB ID 4WH9) was reported to bind to this site recently 272 
[48]. In order to clarify the whole binding mode identification process, the overall workflow is 273 
described in Figure S4. 274 
Molecular docking of NSC663284 was performed using the wild-type crystal structure (PDB 275 
ID: 1QB0). All nine binding poses identified by AutoDock Vina suggest site Ι as the binding 276 
site when the smaller grid box was applied. When the larger grid box was applied, the first 277 
three and last two poses again suggest site I, but poses ranked 4-7 suggest site III as the binding 278 
site. The conformation with the lowest predicted binding energy (−6.6 kcal·mol−1 and −6.1 279 
kcal·mol−1) were named complex 1a and 3a respectively. Both were used as the starting point 280 
for further MD simulations (Figure 3). The binding poses identified by AutoDock 4.2 were 281 
clustered into 13 clusters (Figure S5, Table S3). Cluster 1 and 4 suggest ligand binding to site 282 
I (lowest binding energies of −3.28 and −3.17 kcal mol−1 respectively). However, cluster 3 283 
(with the largest population size) suggests binding to site II (lowest binding energy of −3.19 284 
kcal mol−1). The best ranked conformations from the 7 highest populated clusters were prepared 285 
for further MD simulation as complex 1b-c (for ligand binding in site I, Figure 3) and complex 286 
2a-e (for ligand binding in site II, Figure 4). The binding conformations of clusters 9-11 are 287 
similar, as are their populations (24, 22 and 27, respectively). The best ranked conformation 288 
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from cluster 11 was used for further MD simulation (complex 2f).  Clusters 8, 12 and 13 289 
(population of 1 or 2) were not considered further. 290 
Complex 1b (from AutoDock 4.2) has a very similar conformation as complex 1a (from 291 
AutoDock Vina). Complex 1c shares the same binding site with complexes 1a and 1b, but the 292 
orientation of the quinolinedione ring and the tail moiety is different. Apart from complex 2f 293 
and 2g, all poses in binding site II bind in the same position with the inhibitor interacting with 294 
the P-loop, the short N-terminal loop of helix V and residues 392-394 of the catalytic domain. 295 
The tail moiety of complex 2a interacts with site II directly with the quinolinedione ring 296 
pointing outwards into solvent. Complexes 2b and 2e share a similar pose, with the 297 
quinolinedione ring facing the protein and the tail moiety pointing outwards. The main 298 
difference between 2b and 2e is that the quinolinedione ring is flipped. In complex 2d the 299 
quinolinedione ring is turned by ~90° compared to 2b and 2e, and in complex 2c the tail moiety 300 
instead of the quinolinedione ring is facing the protein. Finally, complex 2f shows a different 301 
position of the ligand, with the quinolinedione ring close to catalytic residue Cys473 (distance 302 
between atom C2 of NSC663284 and the thiolate sulphur of Cys473 is 3.7 Å).  303 
Additional docking experiments were performed with structures obtained from MD simulation 304 
of the apo protein. Clustering of the 1qb0_OXT simulations identified 6 different clusters, and 305 
NSC663284 was docked into representative structures (cluster centroids) for each, using 306 
Autodock Vina. In four cases, the best ranked binding modes were located in site I, and in two 307 
cases, the best ranked binding modes were located in site II. All but one of these best ranked 308 
binding modes was similar to the binding modes already obtained from docking into the crystal 309 
structure (Table S4, Figure S6). The remaining binding mode was similar to that previously 310 
reported by Arantes (1Dm) [22]. Thus, this mode was labelled complex 2g and used for further 311 
investigation with MD simulation.  312 
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In summary, 11 complexes with NSC663284 were used as the starting points for MD 313 
simulation, three poses binding to site I (complex 1a-1c), seven binding to site II (complex 2a-314 
2g) and one binding to site III (complex 3a). The 3 complexes that show the ligand binding to 315 
site I (complexes 1a-1c) include 1 pose suggested by Autodock Vina and 2 poses suggested by 316 
Autodock 4.2. Seven different docking complexes show the ligand binding in site II, including 317 
six obtained from docking with Autodock 4.2 to the crystal structure (complexes 2a-2f) and 318 
one obtained from docking with Autodock Vina to a representative structure from apo protein 319 
MD simulation (complex 2g). One further complex (obtained with a larger grid box for docking 320 
with AutoDock Vina) shows the ligand binding to site III (complex3a). 321 
 322 
Binding site identified by molecular dynamics simulation 323 
To investigate whether the initial binding modes are stable, two 50ns MD simulations were 324 
performed for each of the 10 complexes selected from docking, using the CdC25B model with 325 
a carboxylate C-terminal end at residue Ala151 (OXT). Alongside visual inspection, 326 
displacement of NSC663284 from the starting point was quantified by aligning simulation 327 
snapshots to the Cα atoms of CdC25B that do not show high flexibility (residues 388-412, 418-328 
455, 465-494 and 504-545) and measuring the RMSD (without fitting) of the non-hydrogen 329 
atoms of the ligand (see Table 1,  Figure S7). This measurement, obtained using the initial 330 
binding modes as reference, will be referred to as: ‘ligand displacement RMSD’. 331 
In four out of six simulations with the ligand starting in site I, the ligand does not leave the 332 
binding site in 50 ns of simulation. For complexes 1a and 1b, the ligand leaves in one run (run 333 
2), but stays in the active site in approximately the same pose for the majority of the other (run 334 
1, as indicated by ligand displacement RMSD values below 4 Å, Figure S7), with occasional 335 
small displacement (ligand displacement RMSD values around 4 Å, Figure S7). In runs 2, the 336 
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ligand moves away from the binding site after 20 and 17 ns of simulation for complex 1a and 337 
1b, respectively (ligand displacement RMSD >6 Å, Figure S7). After the quinolinedione ring 338 
leaves the shallow binding pocket, it initially maintains interaction with the C-terminal residues 339 
146-151 (for 20 and 13 ns in 1a and 1b, respectively) before being released in solution 340 
(indicated by ligand displacement RMSD increasing to above 10 Å, Figure S7). For complex 341 
1c, the ligand displacement RMSD rises to about 6 Å at first but then stabilize around 4 Å after 342 
10 ns in run 1 and 20 ns in run 2. Visual inspection confirms that the ligand adjusts its binding 343 
mode in simulation away from complex1c, but the ligand remains bound to binding site I 344 
(Figure 5). 345 
In all simulations of complexes 2a-2g (14 in total), the ligand rapidly moves away from its 346 
initial binding pose (within 0-3 ns, indicated by ligand displacement RMSD >4 Å, Figure S8). 347 
Also in all cases, the ligand moves out of site II completely within 15 ns (ligand displacement 348 
RMSD ≥ 10 Å, Figure S8). In several cases, temporary binding to the protein surface occurs 349 
(before or after release into solution), but the binding sites differ and binding never persists.   350 
In one of the simulations of complex 2b, the ligand moves from site II into site I (see Figure 351 
6). After 10 ns of simulation, the tail moiety has lost all contact with site II residues, and after 352 
10 ns it forms interactions with F475. Once the quinolinedione ring has lost contact with F475 353 
in site II after 12 ns, it forms interactions with Y428 and R482 after 15 ns, similar to the major 354 
binding modes observed in simulations of the ligand bound to site I (see Figure 7 and next 355 
section). After 35 ns, the ligand adopts a stable binding mode in site I with a hydrogen bonding 356 
interaction between Y428 and the oxygen atom on quinolinedione ring. This binding mode 357 
differs from the main binding modes identified, primarily due to the formation of a stacking 358 
interaction with W550 that positions itself between the ligand and R482 (Figure 6, final panel).  359 
In the simulation of complex 3a, the ligand moves away from its initial binding pose (within 360 
30 ns, indicated by ligand displacement RMSD >4 Å, Figure S9A) in run1. In run2, the ligand 361 
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shifts a little out from the initial binding site from 8ns to 22ns, before moving back to its initial 362 
position. After 41 ns, however, the quiinolinedione ring moves out of the pocket, now binding 363 
only with its tail moiety binding at the entrance of the pocket (figure S9C). The ligand could 364 
easily unbind completely once it adopts this pose (which is highly similar to the pose found in 365 
run1 proir to unbinding; figure S9B). It is possible that the quinolinedione ring is somewhat 366 
too big to bind stably in site III. Using the same docking and MD protocol, we investigated the 367 
co-crystallized inhibitor 3M8 (with smaller aromatic moiety than the quinolinedione ring) 368 
which was reported to binding on site III in crystalized structure (PDB ID: 4WH9). It showed 369 
very stable binding in site III in at least in one run (figure S11-S12). 370 
In the starting structures of complex 1a, 1b and 1c, the quinolinedione ring points inward into 371 
the pocket (see Figure 5; complex 1b not show as it is very similar to complex 1a). The main 372 
surrounding residues (within 5 Å) are Arg482, Arg479, Met483, Tyr428, Glu478, Arg544 and 373 
Ser549. Of these, Arg482, Glu478 and Ser549 lie at the entrance of the pocket. Hydrogen bonds 374 
form between (one of the) two oxygen atoms of the quinolinedione ring and the donor atoms 375 
provided by Tyr428 and Arg482. Compared to the quinolinedione ring, the movement of the 376 
tail moiety shows much larger freedom in all simulations (see next section). In all simulations 377 
of complexes 1a, 1b and 1c where the ligand stays bound to the protein, the C-terminus, Arg482 378 
and Glu478 approach each other, which leads to a more closed binding pocket.  379 
In short, MD simulation indicates that stable ligand binding is only possible in site I. This is 380 
consistent with the preference for site I in docking (AutoDock Vina only returns binding poses 381 
in this site and AutoDock 4.2 predicts a marginally higher affinity). The preference for site I 382 
over site II is further illustrated by one of the simulations of complex 2a, where the ligand 383 
moves from site II to site I.  384 
Characterization of the major binding mode in site I  385 
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In the initial MD simulations (see previous section), Ala551 was the C-terminal residue and 386 
was simulated with a carboxylate terminus (OXT). Although Ala551 is the last residue 387 
observed in the crystal structure (only the amide nitrogen), the crystallised construct of Cdc25B 388 
extends to Gln566. The negative charge on the carboxylate terminus may influence the protein-389 
ligand dynamics in site I [45], so we performed additional simulations of the docked complexes 390 
1a and 1c (1b is very similar to 1a, so was not included here). One set of simulations was 391 
performed with a neutral N-methylated C-terminus (NME) and another with two additional 392 
residues (Gly552 and Glu553, according to the sequence) as well as an N-methylated C-393 
terminus (TWO).  394 
Four simulations of the complex_OXT system, two for the complex_NME system and three 395 
for the complex_TWO system show stable binding of the ligand in site I (see Tables 1 and 2, 396 
and also the ‘Ligand displacement RMSD’ in Figure S9). Generally, the tail moiety is more 397 
flexible in these simulations and its conformation changes from the initial docked pose, 398 
whereas the quinolinedione ring stays largely in place (see RMSD values of the quinolinedione 399 
ring and the tail moiety in Figure 7). This observation is in line with the fact that various 400 
compounds with a quinolinedione core structure but different tail moieties have been designed 401 
as effective inhibitors for Cdc25B [9].  402 
Because the tail moiety shows significant flexibility in the simulations, the position of the 403 
quinolinedione ring was used to evaluate the binding modes. All snapshots from the 404 
simulations of each complex system were clustered by calculating the distance between the 405 
center of mass of the N, O and O1 atoms on the ligand (see Figure 7) and the center of mass of 406 
the Cα atoms of Cys426, Leu445 and Arg479 (Figure S1). This revealed a major binding mode, 407 
mode A (Figure 7a), which is mainly observed in simulations of complex 1a and 1b in all three 408 
N-terminal variants (OXT, NME and TWO; see Table 3). For complex 1c_OXT, the first 409 
several nanoseconds of both simulations also show mode A. After that, the ligand adopts 410 
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binding modes which are not clustered into mode A, although the ligand returns to binding 411 
mode A in the last 5 ns in one case. The situation is similar for the simulations of 1c_NME and 412 
1c_TWO, with the notable exception of one run of complex 1c_NME, where the ligand quickly 413 
changes to mode A and then stays in that binding mode for the majority of the simulation. 414 
Binding mode A is characterized by possible hydrogen bond interactions between the ligand 415 
and Tyr428, Arg482, Thr547 and Ser549 (see Figure 7A). In all frames clustered as binding 416 
mode A, the occurrence of these four interactions is 64.0%, 56.8%, 35.7% and 27.1% 417 
respectively (distance cut-off of 3.5 Å, angle cut off of 45°). Clearly, the two oxygen atoms on 418 
the quinolinedione ring play an important role in binding in this mode. No specific interaction 419 
is found with the Cl atom of the ligand, in accordance with the observation that absence of the 420 
Cl substituent does not significantly influence inhibition [20].  421 
A second (minor) binding mode, mode B, was primarily observed in the simulation of complex 422 
1c_TWO. This mode is present for more than 95% of this simulation, but was not found in the 423 
simulations of complex1a_TWO. Mode B is similar to binding mode A (Figure 7B), but no 424 
clear hydrogen bond interactions are formed between the quinolinedione oxygen atoms and 425 
Tyr428 and Arg482. The quinolinedione ring is in a position to form a π-π interaction with 426 
Tyr428, and perhaps an additional (cation-π) interaction with the guanidinium moiety of 427 
Arg482. The fact that mode B was only found in the complex_TWO system is likely due to a 428 
slight conformational change of the terminal helix A: the last several residues (two of which 429 
are only present in the complex_TWO systems) move ‘upwards’ towards helix A instead of 430 
interacting with Arg482. The last 16 residues of the full construct (A551-Q566) are not 431 
observed in the crystal structure [17] and NMR data indicate that the final 20 residues (S549-432 
Q566) are disordered, but can form transient contact with the rest of the protein [46]. The 433 
observed change in position of the final C-terminal residues in the complex_TWO system may 434 
therefore be relevant, which can lead to binding mode B. 435 
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Previously, binding modes of NSC663284 and Cdc25B were suggested based on extensive 436 
docking studies [19]. One possible mode (suggested by AutoDock 4) indicated the 437 
quinolinedione ring hydrogen bonding to Arg482 and Arg544 and the tail moiety positioned 438 
near the P-loop. Another possible mode (in the opposite orientation, suggested by Gold) 439 
indicated the quinolinedione ring positioned near the P-loop and the tail moiety placed between 440 
Arg544 and Arg482. The authors suggested that the first possible mode was more likely as the 441 
ligand binds closer to the catalytic residue Cys473. Although the major mode suggested here 442 
(mode A, figure 7A) also features interactions with Arg482, the position/orientation is 443 
different. We obtained a binding mode through docking similar to the mode suggested in ref. 444 
[19] (complex 2f), but MD simulation indicates that this binding mode is not very stable. 445 
The mode of action of quinolinedione molecules on CdC25B is not yet clear. Sulfhydryl 446 
arylation of Cys473 was shown unlikely to be the main inhibition mechanism [49]. Previously, 447 
quinolinediones have been reported to inhibit Cdc25B through redox cycling and production 448 
of H2O2, leading in turn to the irreversible oxidation of Cys473 [20]. Such an indirect 449 
mechanism does not explain, however, the differences in inhibition observed for 450 
quinolinediones with different substituents leading to changes in steric and electronic 451 
properties [15, 22]. The latter indicates that binding of quinolinediones to CdC25B probably 452 
does play a role, although a direct connection between the quinolinedione ring and the active 453 
site Cys473 may not be necessary to explain the inhibition. Four arginine residues (Arg479, 454 
Arg482, Arg544 and Arg548) are in the vicinity of the catalytic Cys473, and may be involved 455 
in the initial binding of the substrate phosphate moiety. In the model of the Cdk2−CycA 456 
complex binding to Cdc25B suggested by Sohn et al. [50], Arg479 (which is closest to the 457 
catalytic residue Cys473) interacts directly with the phosphate. In our suggested binding mode 458 
A, the ligand directly interacts with Arg482. The presence of the ligand further prevents free 459 
movement of Arg479. The tail moiety further forms transient interactions with residues on 460 
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helix A, including Arg544 and Arg548. The overall pose is similar to that suggested by 461 
molecular docking for a naphthofurandione inhibitor that showed competitive inhibition of 462 
Cdc25B (3-benzoyl-naphtho[1,2-b]furan-4,5-dione or 5169131) [51]. 463 
Notably, the binding of NSC663284 leads to some small, but significant, changes in the 464 
structure and interactions of residues around its binding site (see Supporting Information). 465 
These changes and the presence of NSC663284 are likely to affect the protein-protein 466 
interactions between CdC25B and its protein substrates [49], in a similar fashion as recently 467 
reported for small molecules developed through screening of small-fragment like compounds 468 
using NMR chemical shift perturbations [52].  469 
Conclusions 470 
Through the use of docking and extensive MD simulations, we have identified the likely 471 
binding site of NSC663284 and related quinolinedione inhibitors to the Cdc25B phosphatase. 472 
Initially, 11 possible complexes were obtained by using different docking programs (and 473 
different grid boxes and docking in the crystal structure as well as structures sampled from MD 474 
simulation. In three complexes, the ligand is located in the so-called ‘swimming pool’, as site 475 
between the P-loop and helix A (here labelled site I). Seven complexes present binding modes 476 
with the ligand near the catalytic cysteine (site II) and one complex has the ligand binding in a 477 
region known to be involved in protein-protein interaction (site III). Several 50 ns MD 478 
simulations (at least 2 per complex) show that stable binding of the ligand only occurs in site 479 
I. Clustering identified the likely binding mode of NSC663284, which includes hydrogen 480 
bonding of the quinolinedione oxygens with residues Tyr428 and Arg482. This binding mode 481 
was shown to be largely independent of the treatment of the C-terminal residues in the 482 
simulation (where the unstructured C-terminal part of CdC25B starts). Interactions between 483 
the ligand and Cdc25B lead to a limitation of the freedom around the binding pocket, which in 484 
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turn is likely to affect binding of the protein substrate, leading to the observed inhibition of 485 
quinolinedione compounds. The identification of the quinolinedione binding site will assist in 486 
structure-based drug design of effective inhibitors against CdC25B, an important target for 487 
anti-cancer therapies. 488 
 489 
Acknowledgements 490 
The authors would like to thank Dr. C. J. Woods for helpful discussion and advice. YG and YL 491 
acknowledge ﬁnancial support from National Science Found for Distinguished Young Scholars 492 
of China (21225313), Program for Changjiang Scholars and Innovative Research Team in 493 
University (IRT1030). Major State Special Research Project of China (2016YFA0101200), 494 
Major State Basic Research Development Program of China (973 Program, 2015CB553701), 495 
National Natural Science Foundation of China (NSFC, 21778050). MWvdK and AJM thank 496 
BBSRC and EPSRC for support (EP/G007705/1; BB/L018756/1; BB/M026280). 497 
 498 
References 499 
1. Boutros R, Lobjois V, Ducommun B (2007) CDC25 phosphatases in cancer cells: key 500 
players? Good targets? Nat Rev Cancer 7:495-507. 501 
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Figure Legends 632 
 633 
Fig.1. Chemical structure of NSC663284 with the atom and moiety names used in this study. 634 
 635 
 636 
Fig.2. Cα root mean square fluctuations (RMSF) of the apo protein measured from 50ns MD 637 
simulations of the three C-terminal constructs (1qb0_OXT, 1qb0_NME and 1qb0_TWO), as 638 
well as the value calculated from the temperature (B) factors of the Cdc25B crystal structure 639 




Fig.3. Schematic location of three binding sites in the protein (left) and four complexes with 642 
NSC663284 located in site I and site III obtained from docking. The protein backbone is shown 643 
as cartoon, the ligand as sticks. In the left panel, P-loop residues (without hydrogen atoms) are 644 
shown in ball and stick. 645 
 646 
Fig.4. Seven complexes with NSC663284 located in Site II, obtained from docking. The 647 




Fig.5. Snapshots of MD simulations of (A) complex 1a and (B) complex 1c at 0ns, 25ns and 650 
50ns. The NSC663284 ligand and protein residues within 5 Å of the ligand are shown as sticks, 651 
without hydrogen atoms (for clarity).  652 
 653 
 654 
Fig.6. Movement of ligand from site II to site I. Snapshots of one simulation of complex 2a at 655 
0, 10, 12, 15 and 50ns (top panels); RMSD of protein backbone, RMSD of ligand heavy atoms (after 656 
fitting on protein backbone) and the distance between Y428 and the oxygen atom O on the 657 
quinolinedione ring (bottom). The snapshots illustrate movement of the ligand from site II (0 ns) 658 
to site I (15 ns onwards). The ligand and protein residues within 5 Å of the ligand are shown 659 




Fig.7. Interaction between NSC663284 and Cdc25B in the main binding modes identified. A: 662 
binding mode A; B: binding mode B. Graph below: backbone RMSD of the quinolinedione 663 
ring and tail moiety of the ligand during complex 1a_OXT simulation. The protein structure is 664 
displayed in cartoon, coloured by secondary structure; ligand and residues are displayed as 665 




Table 1. Ligand binding during 25-50ns MD simulation of all 10 complexes (construct 668 
OXT). 669 
 Site I Site II 
Complex 1a 1b 1c 2a 2b 2c 2d 2e 2f 2g 
Run 1 + + + - - - - - - - 
Average 
RMSDa 
1.9 2.4 3.6 16.7 5.6 23.3 28.9 16.5 40.2 28.3 
Run 2 - - + - - - - - - - 
Average 
RMSDa 
34.8 10.7 4.4 11.0 27.0 31.5 29.4 25.0 19.3 28.6 
+ Ligand in the site at the end of the simulation 670 
-  Ligand out of the site at the end of the simulation 671 
a Ligand displacement RMSD in Å: RMSD of ligand non-hydrogen atoms from the initial 672 
docked pose after alignment on protein Cα atoms, see text. 673 
 674 
 675 
Table 2. Ligand binding in 25-50ns of MD simulation of the additional simulations with 676 
adjusted C-terminus (constructs NME and TWO). 677 
 NME TWO 
Complex 1a 1c 1a 1c 
Run 1 - + - + 
Average RMSDa 18.1 2.4 9.8 7.2 
Run 2 - + + + 
Average RMSDa 11.6 4.9 4.7 4.1 
+ Ligand in the site at the end of the simulation 678 
-  Ligand out of the site at the end of the simulation 679 
a Ligand displacement RMSD in Å: RMSD of ligand non-hydrogen atoms from the initial 680 
docked pose after alignment on protein Cα atoms, see text. 681 
 682 
 683 
Table 3. The distribution and occurrence of binding mode A in the nine MD trajectories 684 








1a_1>95%; 1b_1>95%; 1c_1: 0-4.2; 44.6-50.0 ns; 
1c_2: 0-5.32 ns 
59.0% 
49.3% 
NME 1c_1>95%; 1c_2: 0-7.94 ns 53.5% 
TWO 1c_1: 0-3.16 ns; 1c_2: 0-0.86 ns; 1a_2>95% 31.9% 
 686 
